Medical Record Requirements for Pre-Service Reviews

Total Page:16

File Type:pdf, Size:1020Kb

Medical Record Requirements for Pre-Service Reviews Medical Record Requirements for Pre-Service Reviews This document lists medical record requirements for pre-service reviews. These requirements are developed using the clinical criteria in UnitedHealthcare medical policies in conjunction with the guidance provided by UnitedHealthcare physicians and pharmacists with experience in reviewing pre-service requests for coverage. These medical record requirements were developed in an effort to decrease the need for repeated requests for additional information and to improve turnaround time for coverage decisions. Please prepare the suggested materials in advance. We reserve the right to request more information, if necessary. Medical record requirements for case review(s) may vary among various UnitedHealthcare Commercial, UnitedHealthcare Community Plan and UnitedHealthcare Medicare Advantage benefit plans. Please review the requirements for notifications and prior authorization requests at UHCprovider.com/priorauth. These medical record requirements are provided for reference purposes only and may not include all services or codes. Listing of a service or code in this document does not imply that it is a covered or non-covered health service or code. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws. This document is the property of UnitedHealthcare and unauthorized copying, use or distribution of this information is strictly prohibited. It is regularly reviewed, updated and subject to change. Click a service category from the Table of Contents to jump to the applicable section of this document. Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc. Page 1 of 141 Table of Contents Click a service category below to jump to the applicable section of this document. ® Ablative Treatment for Spinal Pain .................... 5 Cardiac Catheterization With or Without Exondys 51 (eteplirsen) ............................... 33 Abortion ......................................................... 5 Angiography ................................................. 20 External Insulin Pump .................................... 34 ® Accidental Dental Services ............................... 5 Cardiac Event Monitoring ................................ 21 Fabrazyme (agalsidase beta) ........................ 34 ® Actemra (tocilizumab) .................................... 5 Catheter Ablation for Atrial Fibrillation .............. 21 Facet Joint Injections for Spinal Pain for Exchange ® Adagen (pegademase bovine) ......................... 6 Certified Nursing Assistant (CAN) or Home Health Plans ........................................................... 35 ® Adakveo (crizanlizumab-tmca) ........................ 6 Aide for Adults 21 and Older for Florida Factor - Von Willebrand Factor (recombinant) .. 35 Airway Clearance Devices................................. 7 Community Plan ............................................ 21 Factor IX ...................................................... 35 ® Akynzeo (netupitant) ..................................... 7 Chimeric Antigen Receptor (CAR) T-Cell Therapy Factor –Products ........................................... 36 ® Aldurazyme (laronidase) ................................ 7 ................................................................... 21 Factor –Products for KS Community Plan ......... 36 ® Alglucosidase alfa ............................................ 7 Cimzia (Certolizumab Pegol) ......................... 22 Factor VIII ................................................... 36 ® ® Alimta (pemetrexed) ..................................... 8 Cinqair (reslizumab) ..................................... 22 Factor VIII (plasma-derived) / von Willebrand Alpha1 Proteinase Inhibitor ............................... 8 Clinical Trials ................................................ 23 Factor Complex (plasma-derived) ................... 38 Ambulance Service ‒ Non-Emergency Air Cochlear Implants & Other Auditory Implants .... 23 Factor X ....................................................... 38 Transport ....................................................... 9 Congenital Heart Disease - Diagnostic and Factor XIII ................................................... 38 Amondys 45™ (Casimersen).............................. 9 Therapeutic Services ...................................... 23 Fasenra® (benralizumab) ............................... 39 Antiemetics For Oncology ............................... 10 Continuous Glucose Monitoring (CGM) .............. 23 Fertility Preservation for Iatrogenic Infertility .... 39 Apheresis ..................................................... 10 Continuous Positive Airway Pressure (CPAP) ..... 24 Fibrinogen Concentrate (plasma-derived) ......... 39 Aranesp® (darbepoetin alfa) ........................... 10 Cosmetic & Reconstructive .............................. 24 Firazyr® (icatibant) ....................................... 40 Arcalyst® (rilonacept) .................................... 10 Crysvita® (burosumab-twza) ........................... 25 Functional Endoscopic Sinus Surgery (FESS) .... 40 Attended Polysomnography (Sleep Study) for Custom Ankle-Foot Orthoses (AFO) and Knee- Functional Neuromuscular Stimulation (FES) .... 41 Evaluation of Sleep Disorders ......................... 11 Ankle-Foot Orthoses (KAFO) ........................... 25 Gamifant® (emapalumab-lzsg) ....................... 41 Autologous Chondrocyte Transplantation .......... 11 Custom Knee Orthotic (KO) ............................ 26 Gastrointestinal Motility Disorders, Diagnosis and Autologous Chondrocyte Transplantation - Implant Decompression Unspecified Nerves .................. 26 Treatment .................................................... 42 material ....................................................... 12 Deep Brain and Cortical Stimulation ................. 26 Gastrointestinal Pathogen Nucleic Acid Detection Automatic External Defibrillator ...................... 12 Denosumab .................................................. 27 Panel Testing For Infectious Diarrhea .............. 42 Balloon Sinus Ostial Dilation (Sinuplasty) ......... 13 Denosumab (Prolia®) for KS Community Plan .... 27 Gender Dysphoria ......................................... 42 Bariatric Surgery ........................................... 14 Drug Testing for Exchange Plans ..................... 28 Genetics and Molecular Pathology Testing Bed Enclosures ............................................. 14 Elaprase® (idursulfase) .................................. 28 (Including BRCA) .......................................... 43 Beds and Mattresses...................................... 15 Elaprase® (idursulfase) for KS Community Plan Givlaari® (givosiran) ...................................... 44 Beds and Mattresses for Exchange Plans .......... 15 Members ...................................................... 29 Glatopa® (glatiramer acetate)......................... 44 Behavioral Health Services ............................. 15 Electric Tumor Treatment Therapy (TIFT) ......... 29 Habilitative Services and Outpatient Rehabilitation Benlysta® (belimumab) .................................. 15 Electrical and Ultrasound Bone Growth Stimulators Therapy for Exchange Plans ........................... 45 Blepharoplasty, Blepharoptosis, and Brow Ptosis ................................................................... 30 Hearing Aids and Devices Including Wearable, Repair ......................................................... 16 Electrical and Ultrasound Bone Growth Stimulators Bone-Anchored and Semi-Implantable ............. 47 Bone or Soft Tissue Healing and Fusion for Exchange Plans ........................................ 30 Hemlibra® (emicizumab-kxwh) ....................... 47 Enhancement Products .................................. 16 Electroencephalographic (EEG) Monitoring and Hemophilia clotting factor, not otherwise classified Botulinum Toxins A and B .............................. 17 Video Recording ............................................ 30 .................................................................. 47 Breast Reconstruction Post Mastectomy and Empliciti® (elotuzumab) for KS Community Plan Herceptin® (trastuzumab) .............................. 48 Poland Syndrome .......................................... 18 Members ...................................................... 31 Herceptin® (trastuzumab) for KS Community Plan Breast Reduction Surgery ............................... 19 Enbrel® (etanercept) ...................................... 31 .................................................................. 48 Breast Repair/ Reconstruction Not Following Enteral Nutrition (Tube Feedings) .................... 31 Hereditary Angioedema (HAE), Treatment and Mastectomy .................................................. 19 Entyvio® (vedolizumab) .................................. 32 Prophylaxis .................................................. 48 Brineura® (cerliponase alfa) ........................... 19 Epoetin alfa .................................................. 32 Home Health Care Services ............................ 49 Camptosar® (irinotecan) for KS Community Plan Epoprostenol ................................................. 32 Home Health Care Services for KS Community members ..................................................... 20 Erbitux® (cefuximab) ..................................... 33 Plan ...........................................................
Recommended publications
  • Duchenne Muscular Dystrophy (DMD) Agents
    Therapeutic Class Overview Duchenne muscular dystrophy (DMD) Agents INTRODUCTION • Duchenne muscular dystrophy (DMD) is 1 of 4 conditions known as dystrophinopathies, which are inherited, X-linked myopathic disorders due to a defect in the dystrophin gene that results in the primary pathologic process of muscle fiber degradation. The hallmark symptom is progressive weakness (Darras 2018[a], Darras 2018[b], Muscular Dystrophy Association [MDA] 2019). The other 3 conditions include: Becker muscular dystrophy (BMD), which is a mild form of DMD; an intermediate presentation between BMD and DMD; and DMD-associated dilated cardiomyopathy, which has little or no clinical ○ skeletal or muscle disease (MDA 2019). • DMD symptom onset is in early childhood, usually between the ages of 2 and 3 years old. The proximal muscles are affected first, followed by the distal limb muscles. Generally, the lower external muscles will be affected before the upper. The affected child may have difficulties jumping, walking, and running (MDA 2019). • The prevalence of DMD ranges from 1 to 2 per 10,000 live male births; female-manifesting carriers are rarer, but can present with a range of symptoms that vary in their severities (Birnkrant et al 2018, Darras 2018[a], Emflaza Food and Drug Administration [FDA] Medical Review 2017). • The clinical course and lifespan of patients with DMD is relatively short. Individuals are usually confined to a wheelchair by age 13, and many die in their late teens or twenties from respiratory insufficiency or cardiomyopathy. Although survival until adulthood is more common now, very few patients survive past the 3rd decade (Darras 2018[a]).
    [Show full text]
  • Vyondys 53™ (Golodirsen)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Vyondys 53™ (Golodirsen) Policy Number: 2021D0088C Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 2 Background.................................................................................... 2 Community Plan Policy Benefit Considerations .................................................................. 3 • Vyondys 53™ (Golodirsen) Clinical Evidence ........................................................................... 3 U.S. Food and Drug Administration ............................................. 3 References ..................................................................................... 4 Policy History/Revision Information ............................................. 4 Instructions for Use ....................................................................... 4 Coverage Rationale See Benefit Considerations Vyondys 53 (golodirsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria: For initial therapy, all of the following: o Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD; and o Submission of medical records (e.g., chart notes, laboratory
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Increased Dystrophin Production with Golodirsen in Patients with Duchenne Muscular Dystrophy
    Published Ahead of Print on March 5, 2020 as 10.1212/WNL.0000000000009233 ARTICLE OPEN ACCESS CLASS OF EVIDENCE Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy Diane E. Frank, PhD, Frederick J. Schnell, PhD, Cody Akana, BS, Saleh H. El-Husayni, BS, Correspondence Cody A. Desjardins, PhD, Jennifer Morgan, PhD, Jay S. Charleston, PhD, Valentina Sardone, PhD, Dr. Muntoni Joana Domingos, MD, George Dickson, PhD, Volker Straub, MD, Michela Guglieri, Eugenio Mercuri, MD, [email protected] Laurent Servais, PhD, and Francesco Muntoni, MD, on behalf of the SKIP-NMD Study Group Neurology® 2020;00:1-13. doi:10.1212/WNL.0000000000009233 Abstract MORE ONLINE Objective Class of Evidence To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen- Criteria for rating treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. therapeutic and diagnostic studies Methods NPub.org/coe Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. Results Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD.
    [Show full text]
  • Robust Extraction, Separation, and Quantitation of Structural Isomer Steroids from Human Plasma by SPE-UHPLC-MS/MS
    TECHNICAL NOTE 21882 Robust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS Authors Application benefits Jon Bardsley1, Kean Woodmansey1, • Separation of structural isomers for accurate detection and Stacy Tremintin2 • Alternative selectivity to C18 phase with an increase in overall resolution of 1Thermo Fisher Scientific, Runcorn, structural isomers UK; 2Thermo Fisher Scientific, Sunnyvale, CA, USA • Stable retention time from extracted plasma • Accurate and precise analytical method across 1000-fold concentration Keywords range Steroid hormone, Vanquish Horizon UHPLC, TSQ Quantiva, Accucore Goal Biphenyl column, LC-MS/MS, SPE Achieve separation of 12 steroid hormones including structural isomers. Comparison to more popular C18 phase is assessed, as well as extraction from human plasma using polymeric solid phase extraction. Introduction Accurate measurement of steroids in plasma is an important requirement in clinical research laboratories. Triple quadrupole mass spectrometry (MS/MS) is now a standard platform in this area for detection due to speed and sensitivity, however this group of compounds contains many structural isomers that cannot be differentiated by MS/MS alone. This may lead to inaccurate analysis by over estimation of concentration levels. Separation prior to MS/MS detection must be achieved, typically by liquid chromatography (LC). An analytical method utilizing LC-MS/MS combined with solid phase extraction of plasma samples is used to remove many matrix interferences,
    [Show full text]
  • 213026Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 OTHER REVIEW(S) IMMUNOGENICITY ASSESSMENT Application Type NDA Application Number 213026 Submit Date 01/10/2020 Received Date 01/10/2020 Division/Office CDER/OND/ON/DNI Review Completion Date 01/10/2021 Product Name Casimersen Proposed Proprie tary AMONDYS 45 Name Error! Bookmark not defined. Pharmacologic Class PMO exon Skipping Applicant Sarepta Therapeutics, Inc. (b) (4) Applicant Proposed Duchenne muscular dystrophy (DMD) in Indication(s) patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. Immunogenicity Assessors Primary Assessor(s) Seth Thacker PhD Secondary Assessor (s) Daniela Verthelyi PhD MD Assessor Recommendation: The sponsor has submitted data for anti-dystrophin antibodies in the casimersen trials. These data were generated using assays that were developed for assessing anti-dystrophin antibodies in patients treated with eteplirsen and golodirsen and have already been deemed fit for use. The sponsor submitted anti-dystrophin ADA data for Study 4045-101, which had 12 patients enrolled No positive samples were found. The FPR for these assays in Study 4045-101 were 1.3%(IgG), 7.9% (IgE), and 39% (IgM) as calculated by the assessor. The sponsors has not submitted an assay for the detection of Casimersen-specific ADAs or provided a plan on how they assess the risk associated with the generation of novel epitopes in the dystrophin formed by exon 45 skipping. PMRs will be issued to the sponsor to develop and validate the assays and to assess the patients in study 4045-101 and 4045-301 for Abs to the product and to the peptide generated through the exon skipping strategy.
    [Show full text]
  • Rxoutlook® 1St Quarter 2019
    ® RxOutlook 1st Quarter 2020 optum.com/optumrx a RxOutlook 1st Quarter 2020 Orphan drugs continue to feature prominently in the drug development pipeline In 1983 the Orphan Drug Act was signed into law. Thirty seven years later, what was initially envisioned as a minor category of drugs has become a major part of the drug development pipeline. The Orphan Drug Act was passed by the United States Congress in 1983 in order to spur drug development for rare conditions with high unmet need. The legislation provided financial incentives to manufacturers if they could demonstrate that the target population for their drug consisted of fewer than 200,000 persons in the United States, or that there was no reasonable expectation that commercial sales would be sufficient to recoup the developmental costs associated with the drug. These “Orphan Drug” approvals have become increasingly common over the last two decades. In 2000, two of the 27 (7%) new drugs approved by the FDA had Orphan Designation, whereas in 2019, 20 of the 48 new drugs (42%) approved by the FDA had Orphan Designation. Since the passage of the Orphan Drug Act, 37 years ago, additional regulations and FDA designations have been implemented in an attempt to further expedite drug development for certain serious and life threatening conditions. Drugs with a Fast Track designation can use Phase 2 clinical trials to support FDA approval. Drugs with Breakthrough Therapy designation can use alternative clinical trial designs instead of the traditional randomized, double-blind, placebo-controlled trial. Additionally, drugs may be approved via the Accelerated Approval pathway using surrogate endpoints in clinical trials rather than clinical outcomes.
    [Show full text]
  • Outpatient Drug Services Handbook
    Texas Medicaid Provider Procedures Manual December 2020 Provider Handbooks Outpatient Drug Services Handbook The Texas Medicaid & Healthcare Partnership (TMHP) is the claims administrator for Texas Medicaid under contract with the Texas Health and Human Services Commission. TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 2 DECEMBER 2020 OUTPATIENT DRUG SERVICES HANDBOOK Table of Contents 1 General Information . 7 1.1 About the Vendor Drug Program. 7 1.2 Pharmacy Enrollment . 8 1.3 Program Contact Information. 8 2 Enrollment . 8 3 Services, Benefits, Limitations, and Prior Authorization. .8 3.1 Prior Authorization Requests . 9 3.2 Electronic Signatures in Prior Authorizations . 9 4 Reimbursement. .10 5 Injectable Medications as a Pharmacy Benefit. .11 6 National Drug Code (NDC) . .12 6.1 Calculating Billable HCPCS and NDC Units . .12 6.1.1 Single-Dose Vials Calculation Examples . 12 6.1.2 Multi-Dose Vials Calculation Examples . 13 6.1.3 Single and Multi-Use Vials . 13 6.1.4 Nonspecific, Unlisted, or Miscellaneous Procedure Codes . 14 7 Outpatient Drugs—Benefits and Limitations. .15 7.1 Abatacept (Orencia) . .15 7.1.1 Prior Authorization for Abatacept (Orencia) . 15 7.2 Adalimumab. .16 7.3 Ado-trastuzumab entansine (Kadcyla). .17 7.4 Alglucosidase Alfa (Myozyme) . .18 7.5 Amifostine . .18 7.6 Antibiotics and Steroids . .22 7.7 Antisense Oligonucleotides (eteplirsen, golodirsen, and nusinersen) . .22 7.7.1 Prior Authorization Requirements. 22 7.7.1.1 Initial Requests (for all Antisense Oligonucleotides) . 23 7.7.1.2 Recertification/Extension Requests (for all Antisense Oligonucleotides). 25 7.7.1.3 Exclusions . 25 7.8 Aripiprazole Lauroxil, (Aristada Initio).
    [Show full text]
  • Effectiveness of Pharmacological Treatments in Duchenne Muscular Dystrophy: a Protocol for a Systematic Review and Meta-Analysis
    Effectiveness of pharmacological treatments in Duchenne muscular dystrophy: A protocol for a systematic review and meta-analysis Morena C.P. Martinez-Vizcaino V. Álvarez-Bueno C. Rodríguez R.F. López E.J. Torres-Costoso A.I. Cavero-Redondo I. Introduction In recent years, important advances have been made in the treatment of Duchenne muscular dystrophy (DMD). This protocol proposes a methodology for carrying out a systematic review and meta-analysis that aims to: (1) improve the evidence of the benefits of different pharmacological treatments in boys with DMD, and (2) compare the benefit of treatments specifically aimed at delaying the progression of disease in the functional outcomes. Methods and analysis This protocol is guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and by the Cochrane Collaboration Handbook. A thorough selection of the literature will be done through the MEDLINE, EMBASE and Web of Science databases. The search will be conducted in English and Spanish. The Risk of Bias 2.0 tool from the Cochrane Collaboration will be used to assess the risk of bias. A narrative synthesis of the data will be performed. Meta-analysis will be conducted for effect of treatment on the 6 min walking distance (6MWD), North Star Ambulatory Assessment and Timed Functional Tests. Subgroup analyses will be performed by age or baseline values of the 6MWD, and overall bias. Ethics and dissemination The approval of an ethical committee is not required. All the included trials will comply with the current ethical standards and the Declaration of Helsinki. The results of this proposed systematic review and meta-analysis will provide a general overview and evidence concerning the effectiveness of pharmacological treatments in Duchenne muscular dystrophy.
    [Show full text]
  • Virtual Posters
    VIRTUAL POSTERS Poster # Title Primary Author First Name Primary Author Last Name City State Brain Tumors/OnCology 200 Clinical and Molecular Features of Atypical Pediatric Neurocytoma: A Case Series Adam Kalawi San Diego CA 201 Atypical molecular features of pediatric tectal glioma: A single institutional series Maayan Yakir San Diego CA 202 Hypercalcemia in Use of the Ketogenic Diet for Treatment of Spinal Lipoma Lila Worden Hartford CT Cognitive/Behavioral Disorders (inCluding Autism) 203 The neurodevelopmental profile of HIVEP2-related disorder Alisa Mo Boston MA 204 Burden of disease in a rare neurologic disorder: caregiver’s perspective on Aicardi Goutières Syndrome Francesco Gavazzi Philadelphia PA 205 Diagnosis delay in Aicardi Goutières Syndrome: a parents’ perspective Francesco Gavazzi Philadelphia PA 206 Validation of the telemedicine application of the Gross Motor Function Measure-88 Francesco Gavazzi Philadelphia PA 207 Altered Cerebellar White Matter in Sensory Processing Dysfunction Is Associated With Impaired Multisensory Integration and Attention Elysa Marco San Rafael CA 208 A comparison of the adaptive and autistic behavior in three developmental epileptic encephalopathies – SLC6A1, SCN2A, STXBP1 Kimberly Goodspeed Dallas TX 209 Spatial topography of cross-frequency coupling during NREM sleep is disrupted in Rett Syndrome Patrick Davis Boston MA 210 Serotonin transporter genotype predicts adaptive behavior outcomes in children with autism Kevin Shapiro Los Angeles CA 211 Clinical and Numerical presentation of Neurocognitive
    [Show full text]
  • Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
    Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value Final Evidence Report August 15, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 University of Illinois at Chicago College of Pharmacy ICER Staff and Consultants Modeling Group Grace A. Lin, MD Catherine Koola, MPH Surrey M. Walton, PhD Associate Professor of Program Manager Associate Professor, Pharmacy Systems, Outcomes and Policy Medicine and Health Policy ICER Assistant Director, Center for Pharmacoepidemiology and University of California, San Pharmacoeconomic Research Francisco University of Illinois at Chicago College of Pharmacy Foluso Agboola, MBBS, MPH Matt Seidner Nicole Boyer, PhD Director, Evidence Synthesis Program Director Postdoctoral Fellow ICER ICER The University of Chicago Noemi Fluetsch, MPH Rick Chapman, PhD, MS Danny Quach, PharmD Research Assistant, Health Director of Health Economics University of Illinois at Chicago College of Pharmacy Economics and Outcomes ICER Research ICER Varun M. Kumar, MBBS, MPH, David Rind, MD, MSc MSc Chief Medical Officer Associate Director of Health ICER Economics ICER The role of the University of Illinois (UIC) College of Pharmacy Sumeyye Samur, PhD, MS Steve Pearson, MD, MSc Modeling Group is limited to the development of the cost- Health Economist President effectiveness model, and the resulting ICER reports do not ICER ICER necessarily represent the views of the UIC. DATE OF PUBLICATION: August 15, 2019 Grace Lin served as the lead author for the report and wrote the background, other benefits, and contextual considerations sections of the report. Foluso Agboola was responsible for the oversight of the systematic review and authorship of the comparative clinical effectiveness section with the support of Ifeoma Otuonye and Noemi Fluetsch.
    [Show full text]
  • 213026Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213026Orig1s000 CLINICAL REVIEW(S) Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping CLINICAL REVIEW Application Type NME, original NDA Application Number(s) NDA 213,026 (IND 118,086) Priority or Standard Priority Submit Date(s) 1/10/20 (submission 1 [clinical, nonclinical]) 6/25/20 (submission 2 [quality, complete NDA]) Received Date(s) 1/10/20; 6/25/20 PDUFA Goal Date 2/25/21 Division/Office DN1 / ON / OND / CDER Reviewer Name(s) David Hosford, ; Xiang Ling (Biometrics); Thomas Biel, Ashutosh Rao (Office of Biotechnology Products [OBP]) Review Completion Date 2/15/21 Established/Proper Name Casimersen (Proposed) Trade Name Amondys 45 Applicant Sarepta Therapeutics, Inc. (Cambridge, MA) Dosage Form(s) concentrated solution in a single use-vial for IV infusion Applicant Proposed Dosing 30mg/kg weekly Regimen(s) Applicant Proposed For the treatment of Duchenne muscular dystrophy (DMD) in Indication(s)/Population(s) patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping Recommendation on Accelerated Approval Regulatory Action Recommended For the treatment of Duchenne muscular dystrophy (DMD) in Indication(s)/Population(s) patients who have a confirmed mutation of the DMD gene that (if applicable) is amenable to exon 45 skipping 1 Reference ID: 4751845 Clinical Review David Hosford, Xiang Ling, Thomas Biel, Ashutosh Rao NDA 213,026: casimersen for DMD amenable to exon 45 skipping Table of Contents Glossary ........................................................................................................................................11 1. Executive Summary...............................................................................................................14 1.1. Product Introduction......................................................................................................14 1.2.
    [Show full text]